Category: Infectious Diseases

Researchers at the UNC School of Medicine’s International Center for the Advancement of Translational Science, Department of Microbiology and Immunology, and Institute for Global Health and Infectious Diseases have demonstrated the important role of human T cells in controlling RSV infection in the absence of an antibody response. Led by...

Chunyan Li is a social and behavioral researcher in the Department of Health Behavior at the Gillings School of Global Public Health applying socially innovative and community-engaged approaches to promote public health in global settings. For her dissertation, she worked with UNC Project-China to assess barriers to PrEP in the province...

HIV virus eradication is a complex health challenge due to its long-lived persistence and how it hides in latently infected cells that escape the body’s immune system. Effective HIV treatments have decreased the likelihood of someone developing AIDS, while helping individuals live long and healthy lives without transmission to sexual...

The NIAID has awarded Arlene Seña, MD, MPH, a member of the Institute for Global Health & Infectious Diseases and professor of infectious diseases, $1.9 million to initiate a longitudinal clinical study over 16 months that will advance diagnostic product development for syphilis, with the potential for additional funding over...

Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November 5, 2020, through...

Michael Sciaudone, MD, an infectious diseases specialist at UNC, has won a 2021 postdoctoral fellowship in tropical infectious diseases from the Burroughs Wellcome Fund-American Society of Tropical Medicine & Hygiene (ASTMH). Three of the coveted fellowships are awarded nationally each year, funding research focused on low and low-middle income countries....

The NIH’s National Institute of Allergy and Infectious Diseases has awarded UNC’s Marcia Hobbs and Alex Duncan a five-year, $3.9 million grant to study how a vaccine recently developed to prevent life-threatening infections caused by group B Neisseria meningitidis, the MenB vaccine, may also protect people from infection with Neisseria...

Hepatitis B virus (HBV) remains endemic throughout sub-Saharan Africa despite the widespread availability of effective childhood vaccines. In the Democratic Republic of the Congo, HBV treatment and birth-dose vaccination programs are not established. UNC School of Medicine researchers led a study to evaluate the feasibility and acceptability of HBV testing...

The Doris Duke Charitable Foundation has awarded Ross Boyce, MD, MSc, a 2021 Clinical Scientist Development Award for his research proposal entitled, “Getting malaria off the back of women and children in western Uganda,” which aims at reducing the incidence of malaria among infants and young children in rural Uganda....

HIV-related mortality has decreased since 1996 due to improved treatments and evolving care guidelines, but the extent to which persons entering HIV care have a higher risk for death over the following years, compared with peers in the general population, has been unclear. Joseph Eron, MD, the Herman and Louise...

U.S. News & World Report has ranked the University of North Carolina-Chapel Hill 11th among universities globally for its infectious diseases program. The Best Global Universities rankings, now in their seventh year, focus on academic research, publications and citations, international collaboration, and overall reputation. This is the first time infectious...

The year was 1993. Alexis Mwanza, then 17, found himself huddled on top of a train, fleeing violence in his home town in the Democratic Republic of Congo by leading nine of his family members 500 miles away to Mbuji Mayi. As a displaced refugee in that city, Mwanza watched...

Research looks at leveraging diagnostic technology to improve management of pediatric infections in low-resource settings Emily Ciccone, MD, MHS, a UNC clinical instructor and infectious diseases fellow, recently won first prize in the clinical research award session of the 2020 annual meeting of the American Society of Tropical Medicine and...

  Last week’s authorization by the U.S. Food and Drug Administration for emergency use of bamlanivimab feels like a shot in the arm, so to speak, for David Wohl, MD, a UNC infectious diseases physician and researcher. A monoclonal antibody developed by Eli Lilly to treat mild to moderate COVID-19,...

On the heels of FDA authorization of convalescent plasma as a treatment for COVID-19, UNC researchers are conducting a clinical trial to determine the safety and efficacy of plasma that includes a higher amount of neutralizing antibodies against SARS-CoV-2. The new Coronavirus-inactivating Plasma (CoVIP) research clinical trial is designed to...

  UNC Institute for Global Health and Infectious Diseases researchers have begun phase 2 and phase 3 evaluations of promising treatments for COVID-19. The UNC School of Medicine joins more than 25 initial sites participating in the clinical trials through ACTIV-2, a public-private partnership sponsored by the NIH’s National Institute...

  It’s hot (especially wearing full PPE), it’s tedious, and it’s critical. A volunteer team of UNC infectious diseases faculty members along with UNC hospitalists has been conducting drive-up testing for COVID-19 in Sanford, NC, about 35 miles south of Chapel Hill, twice a month since June, seeing roughly 1,000...

In February 2020, as bits of data about the SARS-CoV-2 virus started to emerge, Cindy Gay, MD, MPH, and UNC infectious diseases colleagues began meeting to formulate a local response to the virus. They’ve met weekly ever since, resorting to Zoom calls once the university sent employees home in March....

  In the first COVID-19 case series of tocilizumab in the United States, UNC-Chapel Hill researchers report sobering results. They say the drug should be used judiciously until randomized clinical trials determine tocilizumab’s true efficacy. Meanwhile, medical students sidelined from clinical rotations by the virus conducted the research with lightning...

  Large-scale study funded by NIAID and ViiV Healthcare halted early after cabotegravir, dosed every two months, shows higher efficacy than daily oral pill.   The decades-long search for a vaccine to prevent HIV reached a new milestone as results from HPTN 083, a global large-scale study, show that the...